<?xml version="1.0" encoding="UTF-8"?>
<p class="p">For newly emerging infectious diseases in Europe, vaccination campaigns will be feasible where an efficacious vaccine exists. However, few actual vaccines are available on the market for vector-borne diseases. No available studies have estimated the costs of vaccinating the at-risk or high-risk populations in Europe.</p>
